Introduction {#Sec1}
============

The *Cronobacter* genus belongs to the family Enterobacteriaceae and consists of seven species: *C. sakazakii*, *C. malonaticus*, *C. muytjensii*, *C. turicensis*, *C. dublinensis*, *C. universalis* and *C. condimenti* \[[@CR1], [@CR2]\]. In 2002, the International Commission on Microbiological Specifications for Foods (ICMSF) classified *Cronobacter* as pathogenic organisms to a restricted population, endangering their lives and causing serious long-term consequences \[[@CR3]\]. The World Health Organization (WHO) has recognised all *Cronobacter* species as microorganisms pathogenic for human beings \[[@CR4]\]. Among premature neonates and immunocompromised infants, these infections can be life-threatening, with clinical presentations of septicaemia, meningitis and necrotising enterocolitis. The neurological sequelae can be permanent and the mortality rate can be as high as 40--80 % \[[@CR5]\]. Despite the highlighted issues of neonatal infections, the majority of *Cronobacter* infections are in the adult population, especially those suffering from serious underlying disease or malignancy \[[@CR6]\]. *Cronobacter* species are also part of the normal flora carriage \[[@CR7]--[@CR9]\].

The first reported age-profiled data was for 819 *Cronobacter* bacteraemia cases in England and Wales between 1992 and 2007 \[[@CR4]\]. The majority (91 %) of bacteraemia cases were patients \>15 years in age. Holý et al. reported the age profile of *Cronobacter* carriage from a survey of \>45,000 patients from two hospitals sampled from 2005 to 2011 \[[@CR9]\]. The organism was isolated from every age group, with a higher frequency in children less than 14 years of age. The majority of *Cronobacter* spp. isolates were from throat swabs, followed by urine, tracheal aspirates, bronchoalveolar lavage, cannulae and sputum samples. Patrick et al. also reported an age profile for *Cronobacter* infections from an earlier period (2003--2009), which confirmed its prominence in the adult population, especially in urinary tract infections (UTIs) \[[@CR6]\]. However, none of these age profiling studies speciated or genotyped the *Cronobacter* isolates. To date, over 1000 *Cronobacter* strains have been genotyped according to a 7-loci multilocus sequence typing (MLST) scheme \[[@CR10]\]. This genotyping has revealed a prevalence of *C. sakazakii* clonal complex 4 with neonatal meningitis cases and *C. malonaticus* clonal complex 7 with adult infections \[[@CR10]--[@CR12]\]. Whole genome phylogenetic analysis (164 genomes) has confirmed the use of *fusA* for *Cronobacter* speciation \[[@CR10], [@CR13]\].

This study aimed to address this lack of knowledge using the collection of 51 clinical *Cronobacter* strains, which included those from the study by Holý et al. \[[@CR9]\]. These strains were speciated and genotyped using 7-loci MLST, *rpoB* gene sequence analysis, O-antigen typing and pulsed-field gel electrophoresis (PFGE).

Materials and methods {#Sec2}
=====================

Bacterial strains and cultivation {#Sec3}
---------------------------------

Fifty-one clinical *Cronobacter* strains were used in this study. The strains had been collected during a survey of *Cronobacter* carriage by patients from two hospitals, during a 6-year period from May 2007 to August 2013. This includes strains isolated in the previous study by Holý et al. \[[@CR9]\]. Patient information such as age, sex, clinical presentation, isolated site and date of isolation are given in Table [1](#Tab1){ref-type="table"}. Bacterial strains were routinely cultivated on tryptone soya agar (Fluka, UK) at 37 °C overnight.Table 1Source of *Cronobacter* strains used in this studyStrain numberHospitalDepartmentPatient age (years)Patient sexIsolation dateIsolation site1830OlomoucPaediatrics\<1Male09/05/2007Throat swab1829OlomoucPaediatrics1Male04/06/2007Throat swab1828OlomoucPaediatrics2Male12/10/2007Nose swab1831OlomoucPaediatrics3Male06/06/2007Throat swab1832OlomoucPaediatrics3Female27/03/2009Throat swab1999OlomoucPaediatrics3Male30/01/2013Throat swab2020OlomoucPaediatrics5Female26/05/2013Stool1835OlomoucPaediatrics6Male30/03/2012Throat swab2015OlomoucPaediatrics7Female16/08/2013Throat swab2014OlomoucPaediatrics8Male08/04/2013Throat swab1917OlomoucPaediatrics15Male28/10/2012Throat swab1834OlomoucPaediatrics16Male31/05/2010Throat swab2004OlomoucPaediatrics17Female02/03/2013Throat swab1827OlomoucInternal Medicine III76Female09/10/2007Cannula1833OlomoucCMP^a^5Male11/01/2010Stool1838OlomoucAICU^b^63Female10/04/2012Sputum1998ProstějovInternal Medicine (A)49Female22/01/2013Sputum2008ProstějovInternal Medicine (A)68Male12/03/2013Sputum2011ProstějovInternal Medicine (A)68Male31/03/2013USC^d^2006ProstějovInternal Medicine (A)70Female28/02/2013Sputum2007ProstějovInternal Medicine (A)70Female06/03/2013Sputum2022ProstějovInternal Medicine (A)70Female06/03/2013Sputum1842ProstějovInternal Medicine (A)72Female27/06/2012Sputum2005ProstějovInternal Medicine (A)73Female24/02/2013Sputum2021ProstějovInternal Medicine (A)76Female07/04/2013Sputum1841ProstějovInternal Medicine (A)79Female18/06/2012Sputum2003ProstějovInternal Medicine (A)83Male20/02/2013Sputum1915ProstějovInternal Medicine (A)84Female18/10/2012Sputum1996ProstějovInternal Medicine (A)84Female14/01/2013Sputum2010Prostějov-Internal Medicine (A)84Female12/03/2013Throat swab2019ProstějovInternal Medicine (A)87Male10/05/2013Sputum2001ProstějovInternal Medicine (B)68Male29/01/2013SOC^e^2000ProstějovInternal Medicine (B)71Male03/02/2013Rectal Swab2002ProstějovInternal Medicine (B)77Male19/02/2013Sputum1916ProstějovInternal Medicine (B)84Male06/11/2012Sputum2013ProstějovInternal Medicine (B)91Female04/04/2013Sputum2012ProstějovInternal Medicine (C)70Male04/04/2013Sputum2009ProstějovInternal Medicine (C)77Female16/03/2013Tongue swab1903ProstějovInternal Medicine---ICU59Male24/08/2012Sputum1902ProstějovInternal Medicine---ICU69Male21/08/2012Sputum1901ProstějovInternal Medicine---ICU82Male15/08/2012Sputum1997ProstějovICU^c^65Male21/01/2013Sputum1839ProstějovICU73Female12/06/2012SPEG^f^1840ProstějovICU80Female19/06/2012Sputum1836ProstějovSurgery63Male23/05/2012Wound swab1837ProstějovSurgery85Female25/05/2012Wound swab1914ProstějovInfectious Diseases69Male02/10/2012Sputum2018ProstějovInfectious Diseases72Male05/05/2013Sputum2016ProstějovAICU27Male18/04/2013Sputum2017ProstějovAICU27Male22/04/2013Sputum1995ProstějovOutpatient50Male10/01/2013Sputum^a^ *CMP* Clinical and Molecular Pathology^b^ *AICU* Anaesthesiology and Intensive Care Unit^c^ *ICU* Intensive Care Unit^d^ *USC* Urine suction catheter^e^ *SOC* Swab of the oral cavity^f^ *SPEG* Smear from area of percutaneous endoscopic gastrostomy

Phenotyping {#Sec4}
-----------

*Cronobacter* isolates were phenotyped using the ID 32E kit (bioMérieux), according to the manufacturer's instructions. The resultant phenotypic profiles were compared to the bioMérieux online database at [https://apiweb.biomerieux.com](https://apiweb.biomerieux.com/).

PFGE of *Cronobacter* isolates {#Sec5}
------------------------------

PFGE analysis of *Cronobacter* isolates was as previously described by Caubilla-Barron et al. \[[@CR14]\] using the two restriction enzymes *Xbal* and *Spel* (Promega, UK). The bands were separated using a CHEF-DR II System (Bio-Rad, Belgium) at 14 °C, 6 V for 20 h with initial and final switch of 5 and 50 s, respectively. The DNA band profiles were analysed using BioNumerics software version 7.1 (Applied Maths, Belgium). The banding patterns obtained from the PFGE for both *XbaI* and *SpeI* were combined within the Bionumerics software and analysed by the unweighted pair-group method using arithmetic averages (UPGMA). Isolates with band similarity values of less than 95 % were considered to be non-clonal \[[@CR15]\].

Molecular serotyping of *Cronobacter* O-antigens {#Sec6}
------------------------------------------------

*Cronobacter* serotypes were determined using the multiplex polymerase chain reaction (PCR) assay as described by Jarvis et al. and Sun et al. \[[@CR16], [@CR17]\]. The allocated serotypes were uploaded to the *Cronobacter* PubMLST database for open access; [http://PubMLST.org/cronobacter/](http://pubmlst.org/cronobacter/).

DNA extraction {#Sec7}
--------------

DNA was extracted from the target strains using the GenElute™ kit (Sigma, UK), according to the manufacturer's instructions. The DNA concentration was confirmed using a NanoDrop® ND-2000 UV--vis spectrometer (Thermo Scientific, UK), and the DNA was stored at −20 °C for 6 months.

*rpoB* allele sequence analysis {#Sec8}
-------------------------------

*rpoB* allele profiling was performed as described by Brady et al. \[[@CR18]\]. PCR products were visualised on a 1 % agarose gel stained with SYBR Safe. The PCR product (637 bp) was sequenced and aligned with additional sequences from the *Cronobacter* PubMLST database in MEGA (Molecular Evolutionary Genetics Analysis) software version 5.2 \[[@CR19]\] using the ClustalW algorithm. *rpoB* alleles were allocated numbered profiles according to the PubMLST database and were uploaded for open access.

MLST {#Sec9}
----

MLST was performed as previously described by Baldwin et al. \[[@CR20]\] and as given on the *Cronobacter* PubMLST open access database (<http://www.pubmlst.org/cronobacter/>). The seven housekeeping genes amplified were ATP synthase beta chain (*atpD*), elongation factor G (*fusA*), glutaminyl-tRNA synthetase (*glnS*), glutamate synthase large subunit (*gltB*), DNA gyrase subunit B (*gyrB*), translation initiation factor IF-2 (*infB*) and phosphoenolpyruvate synthase (*ppsA*). For multilocus sequence analysis (MLSA), concatenated sequences (3036 bp total length) were aligned in MEGA version 5.2 using the ClustalW algorithm.

Results {#Sec10}
=======

A total of 51 *Cronobacter* strains were characterised by several phenotyping and genotyping methods. Presumptive identification using ID 32E phenotyping identified 49 isolates as *Enterobacter sakazakii*, one strain (1838) as *Pantoea* spp. and the remaining strain (1841) as *E. cloacae*. Since the bioMérieux ID 32E online database does not recognise the *Cronobacter* genus, the strains could not be further identified using this method.

Using the *fusA* sequence analysis and comparison with the *Cronobacter* PubMLST database identified the 51 strains as primarily *C. sakazakii* (33/51), followed by *C. malonaticus* (17/51) and one *C. muytjensii* strain. The strains were then further genotyped using the 7-loci MLST scheme. This supported the species identification-based *fusA* sequence analysis, and further subtyped the isolates (Table [2](#Tab2){ref-type="table"}). The *C. sakazakii* strains were from two sequence types; ST4 (32/51, 63 %) and ST64 (1/51, 2 %). All the *C. malonaticus* strains were ST7 (17/51, 33 %) and the single *C. muytjensii* isolate was ST28 (2 %).Table 2Number of isolated *Cronobacter* strains from various hospital departmentsHospitalDepartmentNumber of *Cronobacter* strains isolatedOlomoucPaediatrics13Internal Medicine1AICU^a^1Pathology1ProstějovInternal Medicine22Internal Medicine---ICU^b^3Surgery2ICU3Infectious Diseases2AICU2Outpatient1Total51^a^ *AICU* Anaesthesiology and Intensive Care Unit^b^ *ICU* Intensive Care Unit

The identification of strains using *rpoB* sequence analysis \[[@CR18]\] and comparison with *rpoB* sequences in the *Cronobacter* PubMLST database agreed with species designation using *fusA* allele sequence analysis (Table [2](#Tab2){ref-type="table"}). There were four different *rpoB* profiles, 1, 18, 35 and 36, which correlated with their 7-loci sequences types. All *C. sakazakii* ST4 and ST64 strains were *rpoB* profiles 1 and 35, respectively. The *C. malonaticus* ST7 strains were *rpoB* profile 18 and *C. muytjensii* ST28 was *rpoB* profile 36. See Table [2](#Tab2){ref-type="table"} for more information.

Comparison with serotyping profiling showed a strong correlation between some sequence types and serotypes. O-serotype *C. sakazakii* O:2 corresponded with *C. sakazakii* ST4. The association was not exclusive however, as *C. sakazakii* ST64 (strain 1995) was also serotype *C. sakazakii* O:2. In addition, the serotype of all (*n* = 17) *C. malonaticus* ST7 strains corresponded with the two designated serotypes *C. malonaticus* O:2 and *C. sakazakii* O:6 according to the schemes of Jarvis et al. and Sun et al., respectively \[[@CR16], [@CR17]\]. Based on *fusA* speciation, *C. malonaticus* O:2 was given as the serotype for these strains (Table [3](#Tab3){ref-type="table"}). No serotype could be determined for the *C. muytjensii* strain as no PCR products were obtained with either PCR serotyping scheme.Table 3Speciation and genotyping of *Cronobacter* spp. from two hospitalsStrainHospitalSpeciesPulsotype*rpoB* allele*fusA* alleleSerotypeSequence type2021Prostějov*C. sakazakii*1211CS O:2ST42022Prostějov*C. sakazakii*1211CS O:2ST41901Prostějov*C. sakazakii*1211CS O:2ST41915Prostějov*C. sakazakii*1211CS O:2ST41996Prostějov*C. sakazakii*1211CS O:2ST41837Prostějov*C. sakazakii*1211CS O:2ST41841Prostějov*C. sakazakii*1211CS O:2ST41842Prostějov*C. sakazakii*1211CS O:2ST42003Prostějov*C. sakazakii*1211CS O:2ST42005Prostějov*C. sakazakii*1211CS O:2ST42007Prostějov*C. sakazakii*1211CS O:2ST42010Prostějov*C. sakazakii*1211CS O:2ST42016Prostějov*C. sakazakii*1211CS O:2ST42019Prostějov*C. sakazakii*1211CS O:2ST42017Prostějov*C. sakazakii*1211CS O:2ST41916Prostějov*C. sakazakii*711CS O:2ST41840Prostějov*C. sakazakii*711CS O:2ST42000Prostějov*C. sakazakii*711CS O:2ST42001Prostějov*C. sakazakii*711CS O:2ST42002Prostějov*C. sakazakii*711CS O:2ST42009Prostějov*C. sakazakii*711CS O:2ST42011Prostějov*C. sakazakii*711CS O:2ST41917Olomouc*C. malonaticus*4187CMal O:2ST71999Olomouc*C. malonaticus*4187CMal O:2ST72004Olomouc*C. malonaticus*4187CMal O:2ST72015Olomouc*C. malonaticus*4187CMal O:2ST72014Olomouc*C. malonaticus*4187CMal O:2ST72020Olomouc*C. malonaticus*4187CMal O:2ST71828Olomouc*C. malonaticus*5187CMal O:2ST71829Olomouc*C. malonaticus*5187CMal O:2ST71830Olomouc*C. malonaticus*5187CMal O:2ST71831Olomouc*C. malonaticus*5187CMal O:2ST71832Olomouc*C. malonaticus*5187CMal O:2ST71903Prostějov*C. sakazakii*1011CS O:2ST41998Prostějov*C. sakazakii*1011CS O:2ST42006Prostějov*C. sakazakii*1011CS O:2ST42008Prostějov*C. sakazakii*1011CS O:2ST41833Olomouc*C. malonaticus*3187CMal O:2ST71834Olomouc*C. malonaticus*3187CMal O:2ST71835Olomouc*C. malonaticus*3187CMal O:2ST71902Prostějov*C. sakazakii*1111CS O:2ST41997Prostějov*C. sakazakii*1111CS O:2ST41914Prostějov*C. malonaticus*1187CMal O:2ST72018Prostějov*C. malonaticus*1187CMal O:2ST71827Olomouc*C. malonaticus*2187CMal O:2ST72013Prostějov*C. sakazakii*811CS O:2ST42012Prostějov*C. sakazakii*911CS O:2ST41839Prostějov*C. sakazakii*1311CS O:2ST41836Prostějov*C. sakazakii*1411CS O:2ST41995Prostějov*C. sakazakii*15358CS O:2ST641838Olomouc*C. muytjensii*63624No PCR productST28

PFGE was used to ascertain whether the strains in each sequence type (i.e. *C. sakazakii* ST4 and *C. malonaticus* ST7) could be further distinguished and whether this could be used to profile the strains from the two hospitals. Using the restriction enzyme XbaI, *C. sakazakii* strains gave 12 to 17 DNA fragments per strain, whereas *C. malonaticus* strains gave 8 to 10 bands (Fig. [1](#Fig1){ref-type="fig"}). Comparable numbers of fragments were obtained using SpeI: 14 to 17 bands for *C. sakazakii* strains and 14 to 16 bands for *C. malonaticus* strains. The *XbaI* restriction enzyme separated the collection into 16 pulsotypes: ten for *C. sakazakii*, five for *C. malonaticus* and one for *C. muytjensii*, while the *SpeI* restriction enzyme divided the collection into 14 pulsotypes: eight for *C. sakazakii*, five for *C. malonaticus* and one for *C. muytjensii*. Combining the PFGE profiles generated with the restriction enzymes *XbaI* and *SpeI* grouped the 51 strains into a total of 15 pulsotypes: nine for *C. sakazakii*, five for *C. malonaticus* and one for *C. muytjensii*. Strains of the same sequence type from different hospital departments were distinguishable by PFGE and are considered in more detail below.Fig. 1Combined *XbaI* and *SpeI* pulsed-field gel electrophoresis (PFGE) profiles of 51 *Cronobacter* strains. *Infect D* Infectious Diseases, *IMIII* Internal Medicine III, *Paed* Paediatric, *CMP* Clinical and Molecular Pathology, *AICU* Anaesthesiology and Intensive Care Unit, *IMA IMB IMC* Internal Medicine A, B, C, respectively, *ICU* Intensive Care Unit, *OP* Outpatient, *TS* throat swab, *NS* nasal swab, *ToS* tongue swab, *OCS* oral cavity swab, *RS* rectal swab, *USC* urine suction catheter, *WS* wound swab, *SPEG* smear from area of percutaneous endoscopic gastrostomy

The isolates from Olomouc hospital formed four distinguishable *C. malonaticus* pulsotypes (PT2 to 5) and one *C. muytjensii* pulsotype (PT6), which were recovered from different age groups of patients from four hospital departments. PT2 was one *C. malonaticus* ST7 strain (1827) isolated in the Internal Medicine Department from the intravenous cannula of a 76-year-old patient in 2007. PT3 was composed of three *C. malonaticus* ST7 strains (1834, 1835, 1833), two of which were isolated from the Paediatric Department and one was from the Clinical and Molecular Pathology Department. The three PT3 strains had been isolated over a 2-year period from throat and stool samples of patients under 16 years of age. The six isolates in PT4 were all *C. malonaticus* ST7 strains. Five had been isolated from the Paediatric Department over a 10-month period from throat swabs and one from a stool sample. The patient ages ranged from 3 to 17 years old. The majority (4/5) of PT5 strains were isolated from the throat and one from nose from the same Paediatric Department. These strains were also *C. malonaticus* ST7 and had been collected over a period of 2 years. The patient ages ranged from 2 months to 3 years. *C. muytjensii* ST28 strain 1838 was in a unique pulsotype (PT6). This strain was isolated in 2012 at the Anaesthesiology and Intensive Care Unit, from the sputum of a 63-year-old patient.

The isolates from Prostějov hospital were recovered from seven departments and were clustered in ten distinguishable *Cronobacter* pulsotypes (Table [3](#Tab3){ref-type="table"}). PT1 was the only *C. malonaticus* pulsotype (strains 1914 and 2018). These were both *C. malonaticus* ST7 strains which were isolated from patients' sputum at the Infectious Disease Department. The collection was over a 7-month period, and the patients were 69 and 72 years in age. All the remaining isolates were strains of *C. sakazakii*, which formed nine pulsotypes (PT7 to 15). Eight of these pulsotypes (PT7 to 14) were composed of 32 strains of *C. sakazakii* ST4. PT15 was composed of one *C. sakazakii* ST64 strain (1995). Most of the 15 *C. sakazakii* ST4 strains in PT12 were isolated from sputum except strains 1837 and 2010, which were isolated from a wound swab and throat swab, respectively. This pulsotype was collected over period of about 1 year and the patients ages ranged from 27 to 87 years. In PT12, 12 isolates were collected from the Internal Medicine Department, two from the Anaesthesiology and Intensive Care Unit and one from the Surgery Department. PT13 and PT14 each contained single *C. sakazakii* ST4 strains; 1839 and 1836, respectively. PT15 contained a single *C. sakazakii* ST64 strain (1995). These strains were isolated from a percutaneous endoscopic gastrostomy smear ICU, wound surgery and the sputum of an outpatient, respectively. The isolations were over a 7-month period and the patient ages ranged from 50 to 73 years. PT7 consisted of seven *C. sakazakii* ST4; strains 1840, 1916 and 2002 were isolated from sputum, strain 2000 from rectal swab, strain 2001 from oral cavity swab, strain 2009 from tongue swab and strain 2011 from section catheter. Six of the isolates were collected from the Internal Medicine department, and strain 1840 was isolated from an Intensive Care Unit patient. The collection was over a 7-month period and all patients were over 68 years of age. PT8, 9, 10 and 11 consisted of eight *C. sakazakii* ST4 strains. All these strains except one (1997) were isolated from sputum at the Internal Medicine Department, whereas strain 1997 was collected from the Intensive Care Unit. The PT8 strain was isolated in 2013 from a 91-year-old patient. PT9 was isolated in 2013 from a 70-year-old patient. PT10 was collected over a roughly 8-month period and the patient ages were between 49 and 70 years old. The two strains in PT11 were collected in 2012 and 2013 and the mean patient age was 67 years (Table [4](#Tab4){ref-type="table"}).Table 4Distribution of *Cronobacter* species and genotype according to hospital and patient details*Cronobacter* speciesSequence typeNo. of isolates (%)Pulsotype (*n*)HospitalPeriod of isolationAge (years)SexSource (*n*)MaleFemale*C. sakazakii*ST432 (63)12 (15), 7 (7), 10 (4), 11 (2), 8 (1), 9 (1), 13 (1), 14 (1)Prostějov12/06/12--10/05/13\>271616Sputum (24), wound swab (2), section catheter (1), tongue swab (1), throat swab (1), oral cavity (1), rectal swab (1), SPEG^a^ (1)*C. sakazakii*ST641 (2)15 (1)Prostějov10/01/20135010Sputum (1)*C. malonaticus*ST717 (33)4 (6), 5 (5), 3 (3), 2 (1)Olomouc06/05/07--16/08/13\<1 to 76125Throat swab (11), faecal material (2), cannula (1), nasal swab (1)1 (2)Prostějov2/10/2012 & 5/05/201369 and 7220Sputum (2)*C. muytjensii*ST281 (2)6 (1)Olomouc10/04/20126301Sputum (1)Total516 years2922^a^ *SPEG* Smear from area of percutaneous endoscopic gastrostomy

goeBURST analysis showed the range of patient ages and sources with *Cronobacter* species (Fig. [2](#Fig2){ref-type="fig"}). *C. sakazakii* ST4 strains were predominantly sputum samples from adults \>70 years in age, whereas *C. malonaticus* ST7 were from throat swabs of children \<6 years old.Fig. 2goeBURST analysis of *Cronobacter* strains

Discussion {#Sec11}
==========

Reported *Cronobacter* infections have primarily concerned infants, especially premature neonates with clinical presentations of necrotising enterocolitis and invasive meningitis \[[@CR21], [@CR22]\]. Although many of these cases have been linked to contaminated reconstituted infant formula \[[@CR23]\], other routes appear to exist, as infections occur in breast-fed infants as well \[[@CR22], [@CR24], [@CR25]\]. The carriage of the organism by adults \[[@CR9]\] and the high incidence of UTIs \[[@CR6]\] indicate that the exposure routes to this bacterium still require further elucidation. In order to have a wider perspective on the exposure to *Cronobacter*, this study speciated and genotyped *Cronobacter* strains from age-profiled clinical isolates, and extended the previous study by Holý et al., who reported the incidence of *Cronobacter* from \>45,000 patients \[[@CR9]\].

Of the 51 strains, the majority were *C. sakazakii* (65 %) and *C. malonaticus* (33 %) (Table [3](#Tab3){ref-type="table"}). The prominence of these two species in clinical isolates has been previously reported in a review of the international *Cronobacter* PubMLST database with \>1000 strains (Forsythe et al. 2014) \[[@CR10]\]. *C. sakazakii* ST4 was the predominant sequence type (32/51 strains) and composed all isolates from Prostějov hospital during a 1-year period. Seventeen *C. malonaticus* ST7 strains were isolated from two hospitals, Olomouc and Prostějov, during the 6-year period from 2007 to 2013. Two further strains were identified as ST64 and ST28, which are *C. sakazakii* and *C. muytjensii*, respectively.

PFGE analysis of isolates revealed that the 35 strains isolated at Prostějov hospital could be divided into three groups. The majority (32/35) of strains belonged to *C. sakazakii* ST4 and were serotype *C. sakazakii* O:2. These strains were isolated from various hospital departments during 2012--2013. Two other group isolates were also recovered from patients in this hospital. These were two strains of *C. malonaticus* ST7 and were serotype *C. malonaticus* O:2, and were the only strains isolated from the Department of Infectious Diseases. The remaining strain was *C. sakazakii* ST64 serotype O:2, which was isolated from an outpatient (50 years old, sputum).

In contrast, all but one of the 16 *Cronobacter* strains isolated from patients at Olomouc hospital were *C. malonaticus* ST7 ; the other isolate was *C. muytjensii*. The *C. malonaticus* strains belonged to the identical sequence type 7 and identical serotype *C. malonaticus* O:2. With two exceptions, all these strains were from patients at the Department of Paediatrics and had an age range of 0--18 years. There were two strains from adults, one *C. malonaticus* from an intravenous cannula and another which was *C. muytjensii* from sputum.

Despite the greater discrimination of strains using PFGE than MLST, isolates from patients for whom there were no known links could not be further differentiated. For example, the *C. sakazakii* ST4, pulsotype 12 strains were isolated from 15 adults (aged 27--85 years) between May 2012 and May 2013. This could be due to the reported high clonality of sequence types within *C. sakazakii* and *C. malonaticus* limiting the discriminatory power of PFGE \[[@CR1], [@CR10]\].

In summary, these clinical isolates were predominated by *C. sakazakii* ST4 (63 %, 32/51) and *C. malonaticus* ST7 (33 %, 17/51). These had been isolated from throat and sputum samples of all age groups, as well as recal and faecal swabs. There was no apparent relatedness between the age or sex of the patient and the *Cronobacter* species isolated. Despite the high clonality of *Cronobacter*, PFGE profiles differentiated strains within each sequence type into 15 pulsotypes. There was almost complete agreement between O-antigen typing and *rpoB* gene sequence analysis and MLST profiling. The majority (43/51) of strains were from the upper respiratory system (i.e. throat swabs and sputum samples) and only three were from faeces and one from urine; two being *C. sakazakii* ST4 and the remaining two *C. malonaticus* ST7. Hence, it is plausible that this small sampling of the lower intestinal tract and UTIs does not reflect the diversity of *Cronobacter* in those samples. Given the high incidence of *Cronobacter* in UTI, this area needs further consideration \[[@CR6]\].

This study shows the value of applying MLST to bacterial population studies with strains from two patient cohorts, combined with PFGE for further discrimination of strains.
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